Using the
FLEXITau platform, researchers mapped 145
PTMs and 195
cleavage sites in human brains.
Machine learning and
mass spectrometry successfully classified six
tauopathies, like Alzheimer’s, by their unique molecular signatures, offering new
diagnostic and drug targets.
References:
- Kumar M, Schlaffner C N, Tang S, et al. Molecular features of human pathological tau distinguish tauopathy-associated dementias[J]. Cell, 2026.